MRPL13 Act as a Novel Therapeutic Target and Could Promote Cell Proliferation in Non-Small Cell Lung Cancer

References

• Brody H. Lung cancer. Nature. 2014;513(7517):S1. doi:10.1038/513S1a25208065
   PubMed Web of Science ®Google Scholar
• Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2020;126(10):2225–2249. doi:10.1002/cncr.3280232162336
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.30207593
   PubMed Web of Science ®Google Scholar
• Lancet T. Lung cancer: some progress, but still a lot more to do. Lancet. 2019;394(10212):1880. doi:10.1016/S0140-6736(19)32795-3
   Web of Science ®Google Scholar
• Slatore C, Sockrider M. Lung cancer prevention. Am J Respir Crit Care Med. 2014;190(10):P7–P8.25398122
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–271.24890451
   PubMed Web of Science ®Google Scholar
• Greber BJ, Bieri P, Leibundgut M, et al. Ribosome. The complete structure of the 55S mammalian mitochondrial ribosome. Science. 2015;348(6232):303–308. doi:10.1126/science.aaa387225837512
   PubMed Web of Science ®Google Scholar
• Li Z, Akar S, Yarkan H, et al. Genome-wide association study in Turkish and Iranian populations identify rare familial Mediterranean fever gene (MEFV) polymorphisms associated with ankylosing spondylitis. PLoS Genet. 2019;15(4):e1008038. doi:10.1371/journal.pgen.100803830946743
   PubMed Web of Science ®Google Scholar
• Lee YK, Lim JJ, Jeoun UW, et al. Lactate-mediated mitoribosomal defects impair mitochondrial oxidative phosphorylation and promote hepatoma cell invasiveness. J Biol Chem. 2017;292(49):20208–20217. doi:10.1074/jbc.M117.80901228978646
   PubMed Web of Science ®Google Scholar
• Tao Z, Suo H, Zhang L, et al. MRPL13 is a prognostic cancer biomarker and correlates with immune infiltrates in breast cancer. Onco Targets Ther. 2020;13:12255–12268. doi:10.2147/OTT.S26399833273831
   PubMed Web of Science ®Google Scholar
• Zhou X, Xiao C, Han T, et al. Prognostic biomarkers related to breast cancer recurrence identified based on logit model analysis. World J Surg Oncol. 2020;18(1):254. doi:10.1186/s12957-020-02026-z32977823
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.23335087
   PubMed Web of Science ®Google Scholar
• Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–546. doi:10.1038/nrc377525056707
   PubMed Web of Science ®Google Scholar
• Zong WX, Rabinowitz JD, White E. Mitochondria and cancer. Mol Cell. 2016;61(5):667–676. doi:10.1016/j.molcel.2016.02.01126942671
   PubMed Web of Science ®Google Scholar
• Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22–35. doi:10.1016/j.cell.2012.03.00322464321
   PubMed Web of Science ®Google Scholar
• Shim H, Chun YS, Lewis BC, Dang CV. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci U S A. 1998;95(4):1511–1516. doi:10.1073/pnas.95.4.15119465046
   PubMed Web of Science ®Google Scholar
• Wong WJ, Qiu B, Nakazawa MS, Qing G, Simon MC. MYC degradation under low O2 tension promotes survival by evading hypoxia-induced cell death. Mol Cell Biol. 2013;33(17):3494–3504. doi:10.1128/MCB.00853-1223816886
   PubMed Web of Science ®Google Scholar
• von Eyss B, Jaenicke LA, Kortlever RM, et al. A MYC-driven change in mitochondrial dynamics limits YAP/TAZ function in mammary epithelial cells and breast cancer. Cancer Cell. 2015;28(6):743–757. doi:10.1016/j.ccell.2015.10.01326678338
   PubMed Web of Science ®Google Scholar
• Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015;5(5):1602–1609.26175931
   PubMed Web of Science ®Google Scholar
• Chang L, Graham PH, Hao J, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013;4(10):e875. doi:10.1038/cddis.2013.40724157869
   PubMed Web of Science ®Google Scholar
• Maric G, Annis MG, MacDonald PA, et al. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity. Oncogene. 2019;38(26):5294–5307. doi:10.1038/s41388-019-0793-730914799
   PubMed Web of Science ®Google Scholar
• Akaike Y, Chibazakura T. Aberrant activation of cyclin A-CDK induces G2/M-phase checkpoint in human cells. Cell Cycle. 2020;19(1):84–96. doi:10.1080/15384101.2019.169311931760882
   PubMed Web of Science ®Google Scholar
• Bo S, Hui H, Li W, et al. Chk1, but not Chk2, is responsible for G2/M phase arrest induced by diallyl disulfide in human gastric cancer BGC823 cells. Food Chem Toxicol. 2014;68:61–70. doi:10.1016/j.fct.2014.03.00724650757
   PubMed Web of Science ®Google Scholar
• Chen H, Shan J, Chen D, et al. CtIP promotes G2/M arrest in etoposide-treated HCT116 cells in a p53-independent manner. J Cell Physiol. 2019;234(7):11871–11881. doi:10.1002/jcp.2782430478995
   PubMed Web of Science ®Google Scholar
• Yuan A, Hsiao YJ, Chen HY, et al. Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. Sci Rep. 2015;5:14273. doi:10.1038/srep1427326399191
   PubMed Web of Science ®Google Scholar
• Tsukumo SI, Yasutomo K. Regulation of CD8(+) T cells and antitumor immunity by notch signaling. Front Immunol. 2018;9:101. doi:10.3389/fimmu.2018.0010129441071
   PubMed Web of Science ®Google Scholar
• Zhang L, Romero P. Metabolic control of CD8(+) T cell fate decisions and antitumor immunity. Trends Mol Med. 2018;24(1):30–48. doi:10.1016/j.molmed.2017.11.00529246759
   PubMed Web of Science ®Google Scholar
• Zander R, Schauder D, Xin G, et al. CD4(+) T cell help is required for the formation of a cytolytic CD8(+) T cell subset that protects against chronic infection and cancer. Immunity. 2019;51(6):1028–1042.e1024. doi:10.1016/j.immuni.2019.10.00931810883
   PubMed Web of Science ®Google Scholar